Review article: dexmedetomidine: does it have potential in palliative medicine?
Dexmedetomidine, is a α( 2) adrenergic agonist approved by the Food and Drug administration for sedation and analgesia. A highly potent α(2) adrenergic agonist, it has quick onset of action, with peak effects within 1 hour of administration. It is metabolized in the liver and eliminated in the urine as a glucuronide. Dexmedetomidine is a substrate and inhibitor of cytochrome oxidase 2D6, but clinical evidence of significant drug interactions is lacking. Clinical trials suggest efficacy for the treatment of delirium in the intensive care unit setting with efficacy comparable to haloperidol and benzodiazepines. Dexmedetomidine also has an opioid-sparing action and can act to enhance analgesia. The purpose of this article is to review the pharmacodynamics and pharmacology of dexmedetomidine, and examine its potential use in the palliative care population, especially with regard to the management of delirium.
Mayo Clinic College of Medicine. prommer.eric@mayo.edu
Eric
E
Prommer
D058647:Adrenergic alpha-2 Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003693:Delirium / Q000188:drug therapy*; D020927:Dexmedetomidine / Q000494:pharmacology / Q000627:therapeutic use*; D003576:Electron Transport Complex IV / Q000037:antagonists & inhibitors; D006801:Humans; D010166:Palliative Care
D058647:Adrenergic alpha-2 Receptor Agonists; D018712:Analgesics, Non-Narcotic; D020927:Dexmedetomidine; D003576:Electron Transport Complex IV